Lyell Immunopharma Inc (LYEL)vsRevolution Medicines Inc (RVMD)
LYEL
Lyell Immunopharma Inc
$12.57
-15.58%
HEALTHCARE · Cap: $279.31M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 2294% more annual revenue ($742,000 vs $31,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. LYEL earns a higher WallStSmart Score of 25/100 (F).
LYEL
Avoid25
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LYEL
The strongest argument for LYEL centers on Price/Book, Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : LYEL
The primary concerns for LYEL are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
LYEL is growing revenue faster at -71.4% — sustainability is the question.
LYEL generates stronger free cash flow (-39M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LYEL scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lyell Immunopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?